Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
05 November 2014Website:
http://www.xenon-pharma.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
XENE Latest News
VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced three poster presentations at the 15th European Epilepsy Congress (EEC) taking place in Rome, Italy. Azetukalner, a novel, potent Kv7 channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage development for multiple indications, including focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS) and major depressive disorder (MDD).
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: Date: Thursday, August 8, 2024 Time: 4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963 for international callers Conference ID: 1631616 The live audio webcast can be accessed on the Investors section of the Xenon website.
Xenon Pharmaceuticals (XENE) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024.
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
- 1(current)
What type of business is Xenon Pharmaceuticals?
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
What sector is Xenon Pharmaceuticals in?
Xenon Pharmaceuticals is in the Healthcare sector
What industry is Xenon Pharmaceuticals in?
Xenon Pharmaceuticals is in the Biotechnology industry
What country is Xenon Pharmaceuticals from?
Xenon Pharmaceuticals is headquartered in Canada
When did Xenon Pharmaceuticals go public?
Xenon Pharmaceuticals initial public offering (IPO) was on 05 November 2014
What is Xenon Pharmaceuticals website?
https://www.xenon-pharma.com
Is Xenon Pharmaceuticals in the S&P 500?
No, Xenon Pharmaceuticals is not included in the S&P 500 index
Is Xenon Pharmaceuticals in the NASDAQ 100?
No, Xenon Pharmaceuticals is not included in the NASDAQ 100 index
Is Xenon Pharmaceuticals in the Dow Jones?
No, Xenon Pharmaceuticals is not included in the Dow Jones index
When was Xenon Pharmaceuticals the previous earnings report?
No data
When does Xenon Pharmaceuticals earnings report?
The next expected earnings date for Xenon Pharmaceuticals is 08 November 2024